Stay updated on LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.

Latest updates to the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page
- Check4 days agoChange DetectedNo significant changes detected between the old and new screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check33 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference4%

- Check40 days agoChange DetectedUpdated software version from v3.0.2 to v3.1.0, reflecting a new release without other substantive content changes.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; no substantive changes to core content detected. Removal of 'Back to Top' is a minor UI change.SummaryDifference0.3%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%

- Check69 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new drug information for Lifileucel and details on various receptors. However, it has also removed specific location details and previous drug information for Durvalumab.SummaryDifference4%

Stay in the know with updates to LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.